The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors for patients with advanced thoracic esophageal squamous cell carcinoma receiving preoperative cisplatin plus 5-fluorouracil (JCOG9907).
Tomoya Yokota
Honoraria - Merck; Merck Serono
Nobutoshi Ando
No relevant relationships to disclose
Hiroyasu Igaki
No relevant relationships to disclose
Masayuki Shinoda
No relevant relationships to disclose
Ken Kato
Research Funding - Daiichi Sankyo; Shionogi
Yuko Kitagawa
Research Funding - Nippon Kayaku
Junki Mizusawa
No relevant relationships to disclose
Hiroshi Katayama
No relevant relationships to disclose
Kenichi Nakamura
No relevant relationships to disclose